Phosphate Co (542123)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trading at a 37% discount to book value with P/B of 0.63, offering asset-level margin of safety
• Low trailing P/E of 10.92 is inexpensive on currently reported earnings
• Sales grew 32.10% YoY, showing demand momentum
• Latest quarter is still profitable: ₹4 Cr net profit on ₹71 Cr sales
• PEG of 0.34 suggests the market is not fully pricing in growth

Concerns

• ROE of 5.90% and ROCE of 7.32% are subpar, indicating weak earnings power on the asset base
• Profit fell 10.21% despite 32.10% sales growth, pointing to margin compression
• Zero dividend yield means no income while waiting for value to unlock
• Piotroski F-score of 4/9 and missing debt/equity and promoter data raise caution

AI Analysis

At ₹154.95, Phosphate Co sells at less than two-thirds of its book value of ₹245.76. Graham taught me to start with a margin of safety, and a P/B of 0.63 gives me that on the balance sheet. But buying a cheap stock is not the same as buying a good business. The company earns only 5.90% on equity and 7.32% on capital employed. That is a sub-par return for a fertilizer business with little pricing power. While sales grew 32.10%, profit fell 10.21%. On latest quarterly revenue of ₹71 Cr, net profit was just ₹4 Cr, roughly a 5.6% margin. That tells me growth is being bought with thin or deteriorating margins. The P/E of 10.92 and PEG of 0.34 look attractive, but only if earnings are sustainable; a declining profit on growing sales is a red flag. The Piotroski F-score of 4/9 reinforces weak financial health. No dividend means I cannot get paid while I wait. And with a market cap of just ₹56 Cr, I worry about liquidity and governance. I am not buying this as a compounder; it is an asset play. The book value provides a cushion, but a mattress stuffed with low-return assets is not a wonderful investment. If management can convert sales momentum into real profit, improve ROE well above 10%, and force better capital allocation, this could become a turnaround. Until then, I would keep it on the watch list, not in the portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer